Emmaus Life Sciences, Inc. (EMMA)

Emmaus Life Sciences Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Year Ending	TTM	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
Net Income	-3.73	-3.73	-10.69	-15.95	1.35	-54.84
Depreciation & Amortization	0.03	0.03	0.05	0.06	0.06	0.07
Share-Based Compensation	1.26	1.26	0.02	0.55	0.74	3.81
Other Operating Activities	0.94	0.94	5.54	14.08	-4.6	46.44
Operating Cash Flow	-1.5	-1.5	-5.07	-1.25	-2.45	-4.52
Capital Expenditures	-0.02	-0.02	-0.03	-0.07	-26.18	-0.06
Acquisitions	1.16	0	5.28	0	30.12	-1.65
Change in Investments	-4.88	-4.88	-8.2	-6.3	-65.72	1.42
Other Investing Activities	3.3	4.46	0.56	-	67.25	-1.2
Investing Cash Flow	-0.43	-0.43	-2.39	-6.38	5.47	-1.48
Common Stock Issued	0	0	0	0	0.14	8.59
Other Financing Activities	2.48	2.48	7.23	7.41	-2.45	-4.71
Financing Cash Flow	2.48	2.48	7.23	7.41	-2.31	3.88
Net Cash Flow	0.53	0.53	-0.26	-0.21	0.72	-2.14
Free Cash Flow	-1.52	-1.52	-5.1	-1.33	-28.63	-4.58
Free Cash Flow Margin	-5.14%	-5.14%	-27.73%	-6.44%	-123.56%	-20.14%
Free Cash Flow Per Share	-0.02	-0.03	-0.10	-0.03	-0.59	-0.11

Sources: The data provider is Financial Modeling Prep and the numbers are sourced from SEC filings.